Hengrui Medicine: Clinical trials of three drugs including SHR-8068 injection have been approved.

Hengrui Medicine announced on the evening of July 31 that its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. have received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the SHR-8068 injection, Atezolizumab injection, and Bevacizumab injection. Clinical trials will be conducted in the near future. Specifically, the study will focus on the combination of SHR-8068 with Atezolizumab and other anti-tumor drugs for the treatment of advanced solid tumors in an open, multicenter IB/II phase clinical trial.